The company, founded in 2019 and based in Leiden, The Netherlands, focuses on spinocerebellar ataxia types 3 and 1, Huntington’s disease, and Rett syndrome, a neurodevelopmental disorder primarily affecting girls. Vico's VICOMER platform designs antisense oligonucleotides to modulate or edit RNA, enabling medical professionals to provide therapy for rare neurological disorders. The company is committed to advancing RNA modulating therapies for patients with severe, genetic neurological disorders. For more information, visit www.vicotx.com.